What financial outlook did Hikma Pharmaceuticals reaffirm for 2026 despite Middle East war-related cost pressures?

Hikma Pharmaceuticals reaffirmed its 2026 group revenue growth guidance of 2% to 4%, with operating profit expected between $720 million and $770 million, and low single-digit revenue growth in its largest injectables business.

Why is Hikma closing its U.S. 503B compounding business, and what does this business entail?

Hikma is closing its 503B compounding business in the U.S. to focus on core operations; this business manufactures bulk medicines for hospitals and clinics—not individual patients—under FDA oversight.

Hikma Pharmaceuticals Maintains 2026 Outlook Despite Middle East War Cost Pressures

Apr 22, 2026

Hikma Pharmaceuticals reaffirmed its 2026 financial guidance, expressing confidence in absorbing Middle East war-related cost increases. The UK drugmaker also decided to close its 503B compounding business to focus on core operations amidst robust demand.

reuters

2026-04-22

Hikma Pharmaceuticals Maintains 2026 Outlook Despite Middle East War Cost Pressures

Hikma Pharmaceuticals Maintains 2026 Outlook Despite Middle East War Cost Pressures

FAQ